- 3-year grant received from the Bill & Melinda Gates Foundation to enhance RNA production technologies
- Grant enables global implementation of the RNA Continuous Manufacturing platform and advancement of
- Process Analytical Technologies (PAT), developed through an MIT project funded by the FDA
- Focused on improving access to RNA therapeutics in Low- and Middle-Income Countries (LMICs)
ReciBioPharm, a division of Recipharm and a leading Contract Development and Manufacturing Organisation (CDMO), has been awarded a three-year grant from the Bill & Melinda Gates Foundation (Gates Foundation). The funding will support the global deployment of xRNA Continuous Manufacturing technologies to LMICs with a strong focus on the development of state-of-the-art inline PAT capabilities and predictive analytics software. ReciBioPharm’s platform will improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes across the biomanufacturing industry.
Vikas Gupta, President of ReciBioPharm, said: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.â€
“Our previously-announced collaboration with MIT has underscored the potential of continuous manufacturing for RNA therapeutics,†added Aaron Cowley, Chief Scientific Officer of ReciBioPharm. “This grant will help to strengthen our role as a pioneer in innovation and support our mission to make lifesaving technologies more accessible.â€
This project exemplifies ReciBioPharm’s dedication to addressing global health challenges by combining advanced technologies, scalable processes, and GMP standards to deliver critical RNA-based solutions worldwide.
